Chinese Journal of Pharmaceuticals, Volume. 56, Issue 7, 965(2025)
The Operation Dilemmas, Cause Analysis and Institutional Improvement of the Market Exclusivity Period System for First Generic Drugs in China
[7] [7] LAWRANCE S, BOND E. ‘Reverse-payment’ patent settlement agreements: non-cash value transfers are not immune from competition law scrutiny [J].J Intellectual Property Law Practice, 2018,13(7): 552-554.
[8] [8] FDA. Marketing of first generic drugs approved by U. S. FDA from January 2010 to June 2017 [EB/OL]. (2021-11-15) [2024-12-9]. https://www.fda.gov/media/154101/download.
Get Citation
Copy Citation Text
FENG Xiangyang, HUANG Lu, LIU Yangyang. The Operation Dilemmas, Cause Analysis and Institutional Improvement of the Market Exclusivity Period System for First Generic Drugs in China[J]. Chinese Journal of Pharmaceuticals, 2025, 56(7): 965
Category:
Received: Feb. 17, 2025
Accepted: Aug. 26, 2025
Published Online: Aug. 26, 2025
The Author Email: